To include your compound in the COVID-19 Resource Center, submit it here.

Medgenics, Baxter deal

Medgenics reinstated an expired deal with Baxter to co-develop Medgenics' biopump technology to produce and deliver Factor VIII to treat hemophilia. The

Read the full 220 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE